Physician profile
Megan S Devine
NPI 1255541108
$8,826.03
in general payments reported to CMS, 2019-2025
43 companies · $2,032 in 2025
The $2,032 reported for 2025 was more than what 76% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,775 · 2020: $314 · 2021: $160 · 2022: $471 · 2023: $555 · 2024: $1,519 · 2025: $2,032.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,006 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,006.40 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $3,718.58 | 2019-2021 | |
| Glaxosmithkline, LLC. | $1,037.34 | 2020-2025 | Trelegy Ellipta, Nucala |
| Boston Scientific Corporation | $854.06 | 2022-2025 | Ams 800 Artificial Urinary Sphincter, General - Erectile Dysfunction, Ams 700 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $431.71 | 2020-2025 | Ofev, Jascayd |
| Genzyme Corporation | $290.25 | 2024-2025 | |
| Insmed, INC. | $264.47 | 2019-2025 | Arikayce, Brinsupri |
| Actelion Pharmaceuticals US, INC. | $244.00 | 2020-2025 | Opsumit, Uptravi, Opsynvi |
| Astrazeneca Pharmaceuticals LP | $230.96 | 2019-2025 | Fasenra, Airsupra |
| United Therapeutics Corporation | $162.07 | 2020-2025 | Tyvaso, Tyvaso |
| Abbvie INC. | $152.69 | 2021-2025 | |
| Vertex Pharmaceuticals Incorporated | $149.65 | 2023-2025 | Trikafta |
| Ambu INC. | $146.64 | 2024 | |
| Mylan Specialty L.P. | $137.50 | 2019-2024 | Tobi Podhaler, Yupelri |
| Vivus LLC | $79.16 | 2024 | Qsymia |
| Innovation Technologies INC | $77.90 | 2024 | Irrisept |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $75.78 | 2025 | Dupixent |
| Ani Pharmaceuticals, INC. | $73.97 | 2024 | Purified Cortrophin Gel |
| Aimmune Therapeutics, INC. | $69.49 | 2024-2025 | Zenpep |
| Inogen, INC. | $59.08 | 2023-2024 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Grifols USA, LLC | $57.10 | 2024-2025 | Prolastin-C Liquid |
| Takeda Pharmaceuticals U.S.A., INC. | $46.60 | 2020-2021 | |
| Philips North America LLC | $45.40 | 2024-2025 | (Ak6) Vest Therapy, Vest Therapy Und |
| Electromed, INC. | $40.93 | 2024-2025 | Smartvest |
| Baxter Healthcare | $40.46 | 2025 | Hillrom - Vest System Model 105 Home Care |
| Optinose US, INC. | $40.21 | 2022 | |
| Harmony Biosciences LLC | $37.56 | 2022-2024 | |
| Sanofi-Aventis U.S. LLC | $35.10 | 2019-2020 | |
| Grifols Shared Services North America, INC. | $35.00 | 2025 | Prolastin-C Liquid |
| Merck Sharp & Dohme LLC | $33.09 | 2021-2025 | Zerbaxa |
| Integra Lifesciences Corporation | $30.73 | 2025 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Viatris Specialty LLC | $23.54 | 2025 | Yupelri |
| Mallinckrodt Hospital Products INC. | $18.86 | 2025 | Acthar |
| Hospira, INC. | $18.47 | 2025 | |
| Astellas Pharma US INC | $17.91 | 2024 | Xtandi |
| Inspire Medical Systems, INC. | $16.90 | 2024 | Inspire |
| Paratek Pharmaceuticals, INC. | $16.58 | 2025 | Nuzyra |
| Pfizer INC. | $16.29 | 2020 |
6 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Megan Devine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.